TipRanks
Go Ultimate55% OFF

Compare Sinopharm Group Co (X2S) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:X2SSinopharm Group CoEUR 1.83EUR 5.75B6.11-14.51%Strong BuyUnlock the DE:X2S analyst price target with TipRanks PremiumDE:X2SUnlock the DE:X2S top-analyst price target with TipRanks Premium
HK:0673China Health GroupHKD 0.26HKD 360.66M-5.29-48.00%―Unlock the HK:0673 analyst price target with TipRanks PremiumDE:X2S vs HK:0673Unlock the HK:0673 top-analyst price target with TipRanks Premium
HK:2607Shanghai Pharmaceuticals Holding CoHKD 11.11HKD 64.52B11.88-9.97%Moderate BuyUnlock the HK:2607 analyst price target with TipRanks PremiumDE:X2S vs HK:2607Unlock the HK:2607 top-analyst price target with TipRanks Premium
HK:1931IVD Medical Holding LimitedHKD 0.36HKD 575.63M-6.46-94.89%―Unlock the HK:1931 analyst price target with TipRanks PremiumDE:X2S vs HK:1931Unlock the HK:1931 top-analyst price target with TipRanks Premium
HK:2192Medlive Technology Co., Ltd.HKD 6.31HKD 4.67B11.63-40.18%Moderate BuyUnlock the HK:2192 analyst price target with TipRanks PremiumDE:X2S vs HK:2192Unlock the HK:2192 top-analyst price target with TipRanks Premium
HK:2289Charmacy Pharmaceutical Co., Ltd. Class HHKD 5.49HKD 592.92M10.831.10%―Unlock the HK:2289 analyst price target with TipRanks PremiumDE:X2S vs HK:2289Unlock the HK:2289 top-analyst price target with TipRanks Premium

Performance Comparison

-100%-75%-50%-25%0%25%50%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:X2SSinopharm Group Co1.83-0.31-14.31%
HK:0673China Health Group0.26-0.36-58.06%
HK:2607Shanghai Pharmaceuticals Holding Co11.11-0.06-0.53%
HK:1931IVD Medical Holding Limited0.35-5.93-94.35%
HK:2192Medlive Technology Co., Ltd.6.30-4.03-38.99%
HK:2289Charmacy Pharmaceutical Co., Ltd. Class H5.490.387.46%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts